These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 2729046)

  • 1. Experimental treatments for HIV-infected patients.
    Am Fam Physician; 1989 Jun; 39(6):330. PubMed ID: 2729046
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term immunotherapy in HIV infection, combined with short-term antiretroviral treatment.
    Bratt G; Eriksson LE; Sandström E; Gilljam G; Hinkula J; Albert J; Redfield R; Wahren B
    Int J STD AIDS; 1999 Aug; 10(8):514-21. PubMed ID: 10471100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on HIV vaccines.
    Meldorf M; Corey L
    STEP Perspect; 1997; 9(2):5-6, 8-9. PubMed ID: 11364929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-HIV drug mechanism.
    Jones IM; Jacob GS
    Nature; 1991 Jul; 352(6332):198. PubMed ID: 1857411
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
    Harrer E; Bäuerle M; Ferstl B; Chaplin P; Petzold B; Mateo L; Handley A; Tzatzaris M; Vollmar J; Bergmann S; Rittmaier M; Eismann K; Müller S; Kalden JR; Spriewald B; Willbold D; Harrer T
    Antivir Ther; 2005; 10(2):285-300. PubMed ID: 15865223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity.
    Tubiana R; Gomard E; Fleury H; Gougeon ML; Mouthon B; Picolet H; Katlama C
    AIDS; 1997 May; 11(6):819-20. PubMed ID: 9143616
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.
    Birx DL; Loomis-Price LD; Aronson N; Brundage J; Davis C; Deyton L; Garner R; Gordin F; Henry D; Holloway W; Kerkering T; Luskin-Hawk R; McNeil J; Michael N; Foster Pierce P; Poretz D; Ratto-Kim S; Renzullo P; Ruiz N; Sitz K; Smith G; Tacket C; Thompson M; Tramont E; Yangco B; Yarrish R; Redfield RR
    J Infect Dis; 2000 Mar; 181(3):881-9. PubMed ID: 10720508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A potential AIDS vaccine tester].
    Fortschr Med; 1988 Jul; 106(22):14-5. PubMed ID: 2851511
    [No Abstract]   [Full Text] [Related]  

  • 9. Glycoscience moves from the laboratory to the clinic.
    Rowe PM
    Lancet; 1999 Jul; 354(9176):402. PubMed ID: 10437881
    [No Abstract]   [Full Text] [Related]  

  • 10. Rabies experiment.
    Koprowski H; Celis E; Curtis P; Dietzschold B; Rupprecht C; Tollis M; Wunner W
    Nature; 1987 Apr 16-22; 326(6114):636. PubMed ID: 3561504
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of N-(3-phenyl-2-propenyl)-1-deoxynojirimycin on the lectin binding to HIV-1 glycoproteins.
    Shimizu H; Tsuchie H; Honma H; Yoshida K; Tsuruoka T; Ushijima H; Kitamura T
    Jpn J Med Sci Biol; 1990 Jun; 43(3):75-87. PubMed ID: 2283726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of therapeutic vaccines of the management of malignant melanoma.
    Dalgleish AG; Souberbielle BE
    Cancer Surv; 1996; 26():289-319. PubMed ID: 8783580
    [No Abstract]   [Full Text] [Related]  

  • 13. Human trials of AIDS vaccines: novel means of passive and active immunotherapy.
    Dalgleish AG
    AIDS; 1988; 2 Suppl 1():S129-31. PubMed ID: 3147663
    [No Abstract]   [Full Text] [Related]  

  • 14. [Trends in research in developing new type of vaccines--aiming at efficacy and safety. Prevention and therapy of herpes simplex].
    Kino Y
    Nihon Rinsho; 1987 Oct; 45(10):2380-3. PubMed ID: 3448273
    [No Abstract]   [Full Text] [Related]  

  • 15. Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase.
    Gruters RA; Neefjes JJ; Tersmette M; de Goede RE; Tulp A; Huisman HG; Miedema F; Ploegh HL
    Nature; 1987 Nov 5-11; 330(6143):74-7. PubMed ID: 2959866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection.
    Habersetzer F; Baumert TF; Stoll-Keller F
    Curr Opin Mol Ther; 2009 Aug; 11(4):456-62. PubMed ID: 19649991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccines and immunology. Overview.
    Laurence J
    AIDS; 1988; 2 Suppl 1():S91-4. PubMed ID: 2852505
    [No Abstract]   [Full Text] [Related]  

  • 18. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
    Perales MA; Schwartz DH; Fabry JA; Lieberman J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):27-35. PubMed ID: 7648281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Web alert. Molecular, viral and cell-based vaccines for disease prevention and therapy.
    Stephens AC
    Curr Opin Mol Ther; 2004 Feb; 6(1):6-7. PubMed ID: 15011774
    [No Abstract]   [Full Text] [Related]  

  • 20. [HIV-1 env glycoprotein gp120 and gp160 expressed in vaccinia virus system and their antigenicity analysis].
    Chen Y; Garcia R; Baralle FE
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1997 Apr; 19(2):120-6. PubMed ID: 10453506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.